Incyte Corporation

Michael D Howell

Kang Sun

Jim Lee

Fiona Kuo

Michael A Pratta

Sherry Owens

Paul Smith

Huiqing Liu

Michael Kuligowski

Kathleen Butler

Beth Rumberger

May Grace E Venturanza

Hao Liu

Kurt Andrew Brown

James Lee

Leandro Luiz Dos Santos

Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.

Biomarkers for vitiligo

This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Ruxolitinib formulation for reduction of itch in atopic dermatitis

Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

Biomarkers for graft-versus-host disease

The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.

Treatment of hidradenitis suppurativa using JAK inhibitors

The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Topical treatment of vitiligo by a JAK inhibitor

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.

JAK1 pathway inhibitors for the treatment of vitiligo

Topical treatment of vitiligo by a jak inhibitor

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing an inflammatory skin disease.

Growing community of inventors

Kennett Square, PA, United States of America

Michael D Howell